Advertisement

Radiotherapy in Gastric Cancer with Peritoneal Carcinomatosis

  • Yang Yang
  • Ju Yang
  • Jing YanEmail author
Chapter

Abstract

Peritoneal dissemination is one of the most common metastatic methods of advanced gastric cancer. Radiotherapy has a positive effect for the prevention or treatment of peritoneal metastasis of gastric cancer. Preoperative neoadjuvant radiochemotherapy and postoperative adjuvant radiochemotherapy can effectively reduce the risk of peritoneal metastasis for patients with locally advanced gastric cancer. For patients who already have peritoneal dissemination, local palliative radiotherapy can effectively relieve the symptoms of local compression and reduce pain. Over the past decade, there are many developments for radiotherapy. Helical tomography, proton radiotherapy, intraoperative radiotherapy, and other new technologies have been used in clinical practice. These clinical applications improved the response rate and reduced adverse reactions for radiotherapy and finally bring benefit to patients.

Keywords

Gastric Cancer Planning Target Volume Advanced Gastric Cancer Peritoneal Carcinomatosis Clinical Target Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Lee CG, Koom WS. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol. 2012;104(3):367–73.CrossRefPubMedGoogle Scholar
  2. 2.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol. 2015;21(9):2711–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol. 2014;21(3):125–33.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sun Z, Nussbaum DP, Speicher PJ, Czito BG, Tyler DS, Blazer 3rd DG. Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. J Surg Oncol. 2015;112(1):46–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, van der Sangen MJ, Beukema JC, Rutten H, Spruit PH, Reinders JG, Richel DJ, van Berge Henegouwen MI, Hulshof MC. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9–10):1522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMedGoogle Scholar
  17. 17.
    Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M, Cats A. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011;11:329.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chaw CL, Niblock PG, Chaw CS, Adamson DJ. The role of palliative radiotherapy for haemostasis in unresectable gastric cancer: a single-institution experience. Ecancermedicalscience. 2014;8:384.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Tey J, Choo BA, Leong CN, Loy EY, Wong LC, Lim K, Lu JJ, Koh WY. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore). 2014;93(22):e118.CrossRefGoogle Scholar
  21. 21.
    Haijun Y, Qiuji W, Zhenming F, Yong H, Zhengkai L, Conghua X, Yunfeng Z, Yahua Z. A new approach to delineating lymph node target volumes for post-operative radiotherapy in gastric cancer: a phase II trial. Radiother Oncol. 2015;116(2):245–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee JA, Ahn YC, Lim do H, Park HC, Asranbaeva MS. Dosimetric and Clinical Influence of 3D Versus 2D Planning in Postoperative Radiation Therapy for Gastric Cancer. Cancer Res Treat. 2015;47(4):727–37.CrossRefPubMedGoogle Scholar
  23. 23.
    Hawrylewicz L, Leszczynski W, Namysl-Kaletka A, Bronclik I, Wydmanski J. Protection of organs at risk during neoadjuvant chemoradiotherapy for gastric cancer based on a comparison between conformal and intensity-modulated radiation therapy. Oncol Lett. 2016;12(1):692–8.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhang T, Liang ZW, Han J, Bi JP, Yang ZY, Ma H. Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol. 2015;10:114.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rochet N, Jensen AD, Sterzing F, Munter MW, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01)—pilot trial of a phase I/II study: study protocol. BMC Cancer. 2007;7:227.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Shetty UM, Shankar S, Engineer R, Chopra S, Gupta S, Maheshwari A, Kerkar R, Shrivastava SK. Image-guided intensity-modulated whole abdominal radiation therapy in relapsed epithelial ovarian cancers: a feasibility study. J Cancer Res Ther. 2013;9(1):17–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, Sohn C, Harms W, Debus J. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer: four-year outcomes. Strahlenther Onkol. 2015;191(7):582–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Adkison JB, Tome W, Seo S, Richards GM, Robins HI, Rassmussen K, Welsh JS, Mahler PA, Howard SP. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):835–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Tome WA, Howard SP. On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br J Radiol. 2007;80(949):32–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Ma CM, Lin MH, Dai XF, Koren S, Klayton T, Wang L, Li JS, Chen L, Price RA. Investigation of pulsed low dose rate radiotherapy using dynamic arc delivery techniques. Phys Med Biol. 2012;57(14):4613–26.CrossRefPubMedGoogle Scholar
  31. 31.
    Martin LM, Marples B, Lynch TH, Hollywood D, Marignol L. Exposure to low dose ionising radiation: molecular and clinical consequences. Cancer Lett. 2014;349(1):98–106.CrossRefPubMedGoogle Scholar
  32. 32.
    Richards GM, Tome WA, Robins HI, Stewart JA, Welsh JS, Mahler PA, Howard SP. Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat. 2009;114(2):307–13.CrossRefPubMedGoogle Scholar
  33. 33.
    Dilworth JT, Krueger SA, Dabjan M, Grills IS, Torma J, Wilson GD, Marples B. Pulsed low-dose irradiation of orthotopic glioblastoma multiforme (GBM) in a pre-clinical model: effects on vascularization and tumor control. Radiother Oncol. 2013;108(1):149–54.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee DY, Chunta JL, Park SS, Huang J, Martinez AA, Grills IS, Krueger SA, Wilson GD, Marples B. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2013;86(5):978–85.CrossRefPubMedGoogle Scholar
  35. 35.
    Dionisi F, Avery S, Lukens JN, Ding X, Kralik J, Kirk M, Roses RE, Amichetti M, Metz JM, Plastaras JP. Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report. Acta Oncol. 2014;53(10):1312–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang Q, Tey J, Peng L, Yang Z, Xiong F, Jiang R, Liu T, Fu S, Lu JJ. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. Radiother Oncol. 2012;102(1):51–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Calvo FA, Sole CV, Obregon R, Gomez-Espi M, Gonzalez-San Segundo C, Gonzalez-Bayon L, Alvarez E, Garcia-Sabrido JL. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol. 2013;15(6):443–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.The Comprehensive Cancer Centre of Drum Tower HospitalMedical School of Nanjing University and Clinical Cancer Institute of Nanjing UniversityNanjingChina

Personalised recommendations